nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—endothelium—melanoma	0.0168	0.113	CbGeAlD
Nedocromil—HSP90AA1—hair follicle—melanoma	0.0165	0.111	CbGeAlD
Nedocromil—HSP90AA1—blood vessel—melanoma	0.0155	0.104	CbGeAlD
Nedocromil—FPR1—head—melanoma	0.0129	0.087	CbGeAlD
Nedocromil—PTGDR—head—melanoma	0.0122	0.0822	CbGeAlD
Nedocromil—HSP90AA1—neck—melanoma	0.0111	0.0747	CbGeAlD
Nedocromil—PTGDR—lymph node—melanoma	0.00854	0.0575	CbGeAlD
Nedocromil—HSP90AA1—eye—melanoma	0.00825	0.0556	CbGeAlD
Nedocromil—HSP90AA1—retina—melanoma	0.00818	0.0551	CbGeAlD
Nedocromil—CYSLTR1—mammalian vulva—melanoma	0.00755	0.0508	CbGeAlD
Nedocromil—HSP90AA1—skin of body—melanoma	0.00718	0.0484	CbGeAlD
Nedocromil—HSP90AA1—mammalian vulva—melanoma	0.00655	0.0441	CbGeAlD
Nedocromil—Disorder sight—Temozolomide—melanoma	0.00543	0.0391	CcSEcCtD
Nedocromil—CYSLTR1—head—melanoma	0.0054	0.0364	CbGeAlD
Nedocromil—HSP90AA1—head—melanoma	0.00468	0.0316	CbGeAlD
Nedocromil—CYSLTR1—lymph node—melanoma	0.00378	0.0255	CbGeAlD
Nedocromil—Arthritis—Vemurafenib—melanoma	0.00378	0.0272	CcSEcCtD
Nedocromil—Otitis media—Temozolomide—melanoma	0.00332	0.0239	CcSEcCtD
Nedocromil—HSP90AA1—lymph node—melanoma	0.00328	0.0221	CbGeAlD
Nedocromil—Eosinophilia—Vemurafenib—melanoma	0.00314	0.0226	CcSEcCtD
Nedocromil—Viral infection—Temozolomide—melanoma	0.00286	0.0206	CcSEcCtD
Nedocromil—Arthritis—Bleomycin—melanoma	0.00229	0.0165	CcSEcCtD
Nedocromil—Rash erythematous—Docetaxel—melanoma	0.00225	0.0162	CcSEcCtD
Nedocromil—Otitis media—Docetaxel—melanoma	0.00221	0.0159	CcSEcCtD
Nedocromil—Ear pain—Temozolomide—melanoma	0.0022	0.0158	CcSEcCtD
Nedocromil—Dysgeusia—Vemurafenib—melanoma	0.00217	0.0156	CcSEcCtD
Nedocromil—Gastroenteritis—Temozolomide—melanoma	0.00212	0.0152	CcSEcCtD
Nedocromil—Nasal congestion—Temozolomide—melanoma	0.00206	0.0148	CcSEcCtD
Nedocromil—Cough—Vemurafenib—melanoma	0.00193	0.0139	CcSEcCtD
Nedocromil—Anaphylactic shock—Vemurafenib—melanoma	0.00181	0.013	CcSEcCtD
Nedocromil—Pneumonia—Bleomycin—melanoma	0.00172	0.0124	CcSEcCtD
Nedocromil—Pneumonia—Dactinomycin—melanoma	0.00161	0.0116	CcSEcCtD
Nedocromil—Bronchitis—Temozolomide—melanoma	0.00156	0.0112	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Vemurafenib—melanoma	0.00156	0.0112	CcSEcCtD
Nedocromil—Fatigue—Vemurafenib—melanoma	0.00156	0.0112	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Temozolomide—melanoma	0.00151	0.0109	CcSEcCtD
Nedocromil—Pneumonia—Carmustine—melanoma	0.00151	0.0108	CcSEcCtD
Nedocromil—Pneumonia—Temozolomide—melanoma	0.00145	0.0105	CcSEcCtD
Nedocromil—Body temperature increased—Vemurafenib—melanoma	0.00143	0.0103	CcSEcCtD
Nedocromil—Pharyngitis—Dactinomycin—melanoma	0.00142	0.0103	CcSEcCtD
Nedocromil—Sinusitis—Temozolomide—melanoma	0.00136	0.00977	CcSEcCtD
Nedocromil—Hypersensitivity—Vemurafenib—melanoma	0.00133	0.00957	CcSEcCtD
Nedocromil—Asthenia—Vemurafenib—melanoma	0.0013	0.00932	CcSEcCtD
Nedocromil—Visual impairment—Carmustine—melanoma	0.00129	0.00932	CcSEcCtD
Nedocromil—Pharyngitis—Temozolomide—melanoma	0.00129	0.00928	CcSEcCtD
Nedocromil—Visual impairment—Temozolomide—melanoma	0.00125	0.00901	CcSEcCtD
Nedocromil—Diarrhoea—Vemurafenib—melanoma	0.00124	0.00889	CcSEcCtD
Nedocromil—Leukopenia—Bleomycin—melanoma	0.0012	0.00863	CcSEcCtD
Nedocromil—Dizziness—Vemurafenib—melanoma	0.00119	0.00859	CcSEcCtD
Nedocromil—Cough—Bleomycin—melanoma	0.00117	0.00842	CcSEcCtD
Nedocromil—Vomiting—Vemurafenib—melanoma	0.00115	0.00826	CcSEcCtD
Nedocromil—Chest pain—Bleomycin—melanoma	0.00114	0.00821	CcSEcCtD
Nedocromil—Rash—Vemurafenib—melanoma	0.00114	0.00819	CcSEcCtD
Nedocromil—Dermatitis—Vemurafenib—melanoma	0.00114	0.00819	CcSEcCtD
Nedocromil—Headache—Vemurafenib—melanoma	0.00113	0.00814	CcSEcCtD
Nedocromil—Leukopenia—Dactinomycin—melanoma	0.00112	0.00805	CcSEcCtD
Nedocromil—Dysgeusia—Temozolomide—melanoma	0.00111	0.00797	CcSEcCtD
Nedocromil—Tremor—Carmustine—melanoma	0.0011	0.00789	CcSEcCtD
Nedocromil—Anaphylactic shock—Bleomycin—melanoma	0.00109	0.00787	CcSEcCtD
Nedocromil—Nausea—Vemurafenib—melanoma	0.00107	0.00772	CcSEcCtD
Nedocromil—Tremor—Temozolomide—melanoma	0.00106	0.00762	CcSEcCtD
Nedocromil—Leukopenia—Carmustine—melanoma	0.00105	0.00754	CcSEcCtD
Nedocromil—Leukopenia—Temozolomide—melanoma	0.00101	0.00728	CcSEcCtD
Nedocromil—Chest pain—Carmustine—melanoma	0.000996	0.00717	CcSEcCtD
Nedocromil—Cough—Temozolomide—melanoma	0.000986	0.0071	CcSEcCtD
Nedocromil—Dyspnoea—Bleomycin—melanoma	0.000975	0.00702	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—melanoma	0.000968	0.00696	CcSEcCtD
Nedocromil—Dry mouth—Temozolomide—melanoma	0.000941	0.00678	CcSEcCtD
Nedocromil—Pain—Bleomycin—melanoma	0.000935	0.00673	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—melanoma	0.000935	0.00673	CcSEcCtD
Nedocromil—Anaphylactic shock—Temozolomide—melanoma	0.000923	0.00664	CcSEcCtD
Nedocromil—Fatigue—Dactinomycin—melanoma	0.000879	0.00633	CcSEcCtD
Nedocromil—Pain—Dactinomycin—melanoma	0.000872	0.00628	CcSEcCtD
Nedocromil—Urticaria—Bleomycin—melanoma	0.000869	0.00625	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—melanoma	0.000866	0.00623	CcSEcCtD
Nedocromil—Body temperature increased—Bleomycin—melanoma	0.000865	0.00622	CcSEcCtD
Nedocromil—Pharyngitis—Docetaxel—melanoma	0.000857	0.00617	CcSEcCtD
Nedocromil—Dyspnoea—Carmustine—melanoma	0.000851	0.00613	CcSEcCtD
Nedocromil—Gastrointestinal pain—Dactinomycin—melanoma	0.000834	0.006	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—melanoma	0.000832	0.00599	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Carmustine—melanoma	0.000824	0.00593	CcSEcCtD
Nedocromil—Dyspnoea—Temozolomide—melanoma	0.000822	0.00592	CcSEcCtD
Nedocromil—Pain—Carmustine—melanoma	0.000816	0.00588	CcSEcCtD
Nedocromil—Dyspepsia—Temozolomide—melanoma	0.000812	0.00585	CcSEcCtD
Nedocromil—Abdominal pain—Dactinomycin—melanoma	0.000806	0.0058	CcSEcCtD
Nedocromil—Body temperature increased—Dactinomycin—melanoma	0.000806	0.0058	CcSEcCtD
Nedocromil—Hypersensitivity—Bleomycin—melanoma	0.000806	0.0058	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Temozolomide—melanoma	0.000796	0.00573	CcSEcCtD
Nedocromil—Fatigue—Temozolomide—melanoma	0.000795	0.00573	CcSEcCtD
Nedocromil—Pain—Temozolomide—melanoma	0.000789	0.00568	CcSEcCtD
Nedocromil—Asthenia—Bleomycin—melanoma	0.000785	0.00565	CcSEcCtD
Nedocromil—Gastrointestinal pain—Carmustine—melanoma	0.000781	0.00562	CcSEcCtD
Nedocromil—Body temperature increased—Carmustine—melanoma	0.000755	0.00543	CcSEcCtD
Nedocromil—Abdominal pain—Carmustine—melanoma	0.000755	0.00543	CcSEcCtD
Nedocromil—Gastrointestinal pain—Temozolomide—melanoma	0.000754	0.00543	CcSEcCtD
Nedocromil—Hypersensitivity—Dactinomycin—melanoma	0.000751	0.00541	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—melanoma	0.000736	0.0053	CcSEcCtD
Nedocromil—Urticaria—Temozolomide—melanoma	0.000733	0.00528	CcSEcCtD
Nedocromil—Asthenia—Dactinomycin—melanoma	0.000732	0.00527	CcSEcCtD
Nedocromil—Body temperature increased—Temozolomide—melanoma	0.000729	0.00525	CcSEcCtD
Nedocromil—Abdominal pain—Temozolomide—melanoma	0.000729	0.00525	CcSEcCtD
Nedocromil—Hypersensitivity—Carmustine—melanoma	0.000703	0.00506	CcSEcCtD
Nedocromil—Diarrhoea—Dactinomycin—melanoma	0.000698	0.00502	CcSEcCtD
Nedocromil—Vomiting—Bleomycin—melanoma	0.000695	0.00501	CcSEcCtD
Nedocromil—Rash—Bleomycin—melanoma	0.00069	0.00496	CcSEcCtD
Nedocromil—Dermatitis—Bleomycin—melanoma	0.000689	0.00496	CcSEcCtD
Nedocromil—Asthenia—Carmustine—melanoma	0.000685	0.00493	CcSEcCtD
Nedocromil—Hypersensitivity—Temozolomide—melanoma	0.00068	0.00489	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—melanoma	0.000673	0.00484	CcSEcCtD
Nedocromil—Asthenia—Temozolomide—melanoma	0.000662	0.00476	CcSEcCtD
Nedocromil—Cough—Docetaxel—melanoma	0.000656	0.00472	CcSEcCtD
Nedocromil—Diarrhoea—Carmustine—melanoma	0.000653	0.0047	CcSEcCtD
Nedocromil—Nausea—Bleomycin—melanoma	0.00065	0.00468	CcSEcCtD
Nedocromil—Vomiting—Dactinomycin—melanoma	0.000649	0.00467	CcSEcCtD
Nedocromil—Rash—Dactinomycin—melanoma	0.000643	0.00463	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—melanoma	0.00064	0.00461	CcSEcCtD
Nedocromil—Dizziness—Carmustine—melanoma	0.000631	0.00454	CcSEcCtD
Nedocromil—Diarrhoea—Temozolomide—melanoma	0.000631	0.00454	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—melanoma	0.000626	0.00451	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—melanoma	0.000613	0.00442	CcSEcCtD
Nedocromil—Dizziness—Temozolomide—melanoma	0.00061	0.00439	CcSEcCtD
Nedocromil—Vomiting—Carmustine—melanoma	0.000607	0.00437	CcSEcCtD
Nedocromil—Nausea—Dactinomycin—melanoma	0.000606	0.00436	CcSEcCtD
Nedocromil—Rash—Carmustine—melanoma	0.000602	0.00433	CcSEcCtD
Nedocromil—Dermatitis—Carmustine—melanoma	0.000601	0.00433	CcSEcCtD
Nedocromil—Headache—Carmustine—melanoma	0.000598	0.00431	CcSEcCtD
Nedocromil—Vomiting—Temozolomide—melanoma	0.000587	0.00422	CcSEcCtD
Nedocromil—Rash—Temozolomide—melanoma	0.000582	0.00419	CcSEcCtD
Nedocromil—Dermatitis—Temozolomide—melanoma	0.000581	0.00418	CcSEcCtD
Nedocromil—Headache—Temozolomide—melanoma	0.000578	0.00416	CcSEcCtD
Nedocromil—Nausea—Carmustine—melanoma	0.000567	0.00408	CcSEcCtD
Nedocromil—Nausea—Temozolomide—melanoma	0.000548	0.00394	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—melanoma	0.000547	0.00394	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—melanoma	0.00054	0.00389	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—melanoma	0.00053	0.00381	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—melanoma	0.000529	0.00381	CcSEcCtD
Nedocromil—Pain—Docetaxel—melanoma	0.000525	0.00378	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—melanoma	0.000502	0.00361	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—melanoma	0.000485	0.00349	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—melanoma	0.000485	0.00349	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—melanoma	0.000452	0.00325	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—melanoma	0.00044	0.00317	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—melanoma	0.00042	0.00302	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—melanoma	0.000406	0.00292	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—melanoma	0.00039	0.00281	CcSEcCtD
Nedocromil—Rash—Docetaxel—melanoma	0.000387	0.00278	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—melanoma	0.000386	0.00278	CcSEcCtD
Nedocromil—Headache—Docetaxel—melanoma	0.000384	0.00277	CcSEcCtD
Nedocromil—Nausea—Docetaxel—melanoma	0.000364	0.00262	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—HIF1A—melanoma	5.6e-05	7.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MAPK3—melanoma	5.57e-05	7.82e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—melanoma	5.56e-05	7.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—melanoma	5.55e-05	7.79e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—melanoma	5.55e-05	7.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—ERBB2—melanoma	5.52e-05	7.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD80—melanoma	5.48e-05	7.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KIT—melanoma	5.48e-05	7.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TNF—melanoma	5.46e-05	7.66e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CB—melanoma	5.45e-05	7.65e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—melanoma	5.42e-05	7.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—melanoma	5.42e-05	7.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGF—melanoma	5.41e-05	7.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—melanoma	5.41e-05	7.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PRKCA—melanoma	5.4e-05	7.58e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—melanoma	5.37e-05	7.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ERCC2—melanoma	5.36e-05	7.52e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—melanoma	5.36e-05	7.52e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KDR—melanoma	5.35e-05	7.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK3—melanoma	5.32e-05	7.46e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SOCS1—melanoma	5.31e-05	7.46e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK3—melanoma	5.31e-05	7.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MAPK1—melanoma	5.3e-05	7.44e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—S100B—melanoma	5.3e-05	7.44e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—melanoma	5.24e-05	7.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS2—melanoma	5.22e-05	7.32e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—melanoma	5.2e-05	7.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOTCH1—melanoma	5.17e-05	7.25e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—melanoma	5.17e-05	7.25e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FN1—melanoma	5.15e-05	7.23e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK3—melanoma	5.13e-05	7.2e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—melanoma	5.12e-05	7.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CASP8—melanoma	5.1e-05	7.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB4—melanoma	5.07e-05	7.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD80—melanoma	5.06e-05	7.11e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—melanoma	5.06e-05	7.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK1—melanoma	5.06e-05	7.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—melanoma	5.06e-05	7.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KIT—melanoma	5.05e-05	7.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APC—melanoma	5.05e-05	7.09e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK1—melanoma	5.05e-05	7.09e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—melanoma	5.05e-05	7.09e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOTCH1—melanoma	5.04e-05	7.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—melanoma	5.04e-05	7.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN2B—melanoma	5.03e-05	7.05e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—melanoma	5.01e-05	7.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—melanoma	5.01e-05	7.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGF—melanoma	5e-05	7.01e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—melanoma	4.99e-05	7e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—melanoma	4.98e-05	6.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CD80—melanoma	4.94e-05	6.93e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APC—melanoma	4.93e-05	6.92e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—melanoma	4.93e-05	6.92e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KIT—melanoma	4.93e-05	6.92e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—melanoma	4.93e-05	6.92e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—melanoma	4.88e-05	6.85e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK1—melanoma	4.88e-05	6.85e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—melanoma	4.88e-05	6.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGF—melanoma	4.87e-05	6.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CD86—melanoma	4.86e-05	6.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAP2K1—melanoma	4.84e-05	6.8e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—melanoma	4.83e-05	6.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EDN1—melanoma	4.82e-05	6.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—melanoma	4.81e-05	6.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—melanoma	4.78e-05	6.71e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—melanoma	4.77e-05	6.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BRAF—melanoma	4.75e-05	6.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—melanoma	4.74e-05	6.65e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK3—melanoma	4.72e-05	6.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—melanoma	4.72e-05	6.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CSF2—melanoma	4.71e-05	6.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF1—melanoma	4.71e-05	6.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—melanoma	4.71e-05	6.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NFKB1—melanoma	4.69e-05	6.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—melanoma	4.64e-05	6.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—E2F1—melanoma	4.61e-05	6.47e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—melanoma	4.61e-05	6.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FGF2—melanoma	4.61e-05	6.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—melanoma	4.6e-05	6.45e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—melanoma	4.6e-05	6.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFRA—melanoma	4.57e-05	6.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ITGB3—melanoma	4.52e-05	6.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PRKCA—melanoma	4.52e-05	6.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1—melanoma	4.52e-05	6.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK1—melanoma	4.49e-05	6.31e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—melanoma	4.49e-05	6.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAP2K1—melanoma	4.47e-05	6.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—melanoma	4.45e-05	6.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—melanoma	4.44e-05	6.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SPP1—melanoma	4.43e-05	6.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP2K2—melanoma	4.42e-05	6.2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—melanoma	4.4e-05	6.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—melanoma	4.39e-05	6.16e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—melanoma	4.39e-05	6.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2—melanoma	4.38e-05	6.14e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAP2K1—melanoma	4.36e-05	6.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IFNG—melanoma	4.34e-05	6.08e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—melanoma	4.34e-05	6.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MDM2—melanoma	4.31e-05	6.05e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—melanoma	4.29e-05	6.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—melanoma	4.25e-05	5.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FGF2—melanoma	4.25e-05	5.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—melanoma	4.25e-05	5.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—melanoma	4.24e-05	5.96e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—melanoma	4.24e-05	5.95e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—melanoma	4.24e-05	5.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—melanoma	4.23e-05	5.94e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—melanoma	4.21e-05	5.91e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—melanoma	4.2e-05	5.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—melanoma	4.2e-05	5.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—melanoma	4.2e-05	5.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RAC1—melanoma	4.19e-05	5.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD4—melanoma	4.19e-05	5.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGF2—melanoma	4.15e-05	5.82e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—melanoma	4.1e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARG—melanoma	4.09e-05	5.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—melanoma	4.06e-05	5.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—melanoma	4.06e-05	5.7e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—melanoma	4.06e-05	5.69e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK3—melanoma	4.03e-05	5.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—melanoma	4.02e-05	5.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MDM2—melanoma	3.98e-05	5.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—melanoma	3.94e-05	5.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—melanoma	3.92e-05	5.51e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—melanoma	3.92e-05	5.5e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—melanoma	3.91e-05	5.49e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—melanoma	3.9e-05	5.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—melanoma	3.89e-05	5.46e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—melanoma	3.88e-05	5.45e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—melanoma	3.88e-05	5.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—melanoma	3.87e-05	5.44e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD4—melanoma	3.87e-05	5.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—melanoma	3.85e-05	5.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KDR—melanoma	3.84e-05	5.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—melanoma	3.84e-05	5.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK1—melanoma	3.83e-05	5.37e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—melanoma	3.83e-05	5.37e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—melanoma	3.83e-05	5.37e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—melanoma	3.78e-05	5.3e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—melanoma	3.75e-05	5.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—melanoma	3.72e-05	5.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—melanoma	3.72e-05	5.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FN1—melanoma	3.7e-05	5.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ALB—melanoma	3.67e-05	5.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—melanoma	3.63e-05	5.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—melanoma	3.63e-05	5.1e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—melanoma	3.63e-05	5.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—melanoma	3.63e-05	5.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH1—melanoma	3.62e-05	5.08e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—melanoma	3.62e-05	5.08e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—melanoma	3.61e-05	5.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NFKB1—melanoma	3.61e-05	5.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—melanoma	3.59e-05	5.03e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—melanoma	3.58e-05	5.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—melanoma	3.55e-05	4.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CD80—melanoma	3.55e-05	4.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—melanoma	3.54e-05	4.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KIT—melanoma	3.54e-05	4.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APC—melanoma	3.54e-05	4.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—melanoma	3.51e-05	4.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGF—melanoma	3.5e-05	4.91e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—melanoma	3.48e-05	4.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—melanoma	3.47e-05	4.87e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—melanoma	3.46e-05	4.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—melanoma	3.45e-05	4.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—melanoma	3.43e-05	4.82e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—melanoma	3.38e-05	4.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—melanoma	3.35e-05	4.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—melanoma	3.35e-05	4.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—melanoma	3.35e-05	4.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—melanoma	3.33e-05	4.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—melanoma	3.32e-05	4.66e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—melanoma	3.28e-05	4.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—melanoma	3.27e-05	4.59e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—melanoma	3.27e-05	4.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKB1—melanoma	3.25e-05	4.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—melanoma	3.24e-05	4.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—melanoma	3.24e-05	4.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1—melanoma	3.24e-05	4.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—melanoma	3.23e-05	4.54e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—melanoma	3.22e-05	4.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—melanoma	3.21e-05	4.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—melanoma	3.19e-05	4.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP2K1—melanoma	3.13e-05	4.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—melanoma	3.11e-05	4.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK3—melanoma	3.1e-05	4.35e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—melanoma	3.07e-05	4.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—melanoma	2.99e-05	4.2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—melanoma	2.99e-05	4.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF2—melanoma	2.98e-05	4.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—melanoma	2.95e-05	4.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK1—melanoma	2.95e-05	4.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—melanoma	2.95e-05	4.13e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—melanoma	2.94e-05	4.13e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—melanoma	2.92e-05	4.1e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—melanoma	2.91e-05	4.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK3—melanoma	2.86e-05	4.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—melanoma	2.8e-05	3.93e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK3—melanoma	2.79e-05	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—melanoma	2.79e-05	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—melanoma	2.78e-05	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—melanoma	2.78e-05	3.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—melanoma	2.75e-05	3.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK1—melanoma	2.72e-05	3.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—melanoma	2.72e-05	3.82e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—melanoma	2.71e-05	3.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—melanoma	2.71e-05	3.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—melanoma	2.71e-05	3.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK1—melanoma	2.65e-05	3.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—melanoma	2.65e-05	3.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—melanoma	2.61e-05	3.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—melanoma	2.57e-05	3.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—melanoma	2.56e-05	3.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—melanoma	2.55e-05	3.57e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—melanoma	2.51e-05	3.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—melanoma	2.49e-05	3.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—melanoma	2.49e-05	3.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—melanoma	2.43e-05	3.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—melanoma	2.4e-05	3.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—melanoma	2.37e-05	3.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—melanoma	2.36e-05	3.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—melanoma	2.36e-05	3.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—melanoma	2.35e-05	3.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—melanoma	2.34e-05	3.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKB1—melanoma	2.33e-05	3.27e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—melanoma	2.3e-05	3.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—melanoma	2.26e-05	3.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—melanoma	2.23e-05	3.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—melanoma	2.18e-05	3.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—melanoma	2.13e-05	2.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—melanoma	2.12e-05	2.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—melanoma	2.1e-05	2.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—melanoma	2.09e-05	2.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—melanoma	2.09e-05	2.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—melanoma	2.09e-05	2.93e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—melanoma	2.04e-05	2.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK3—melanoma	2e-05	2.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—melanoma	1.98e-05	2.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—melanoma	1.95e-05	2.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—melanoma	1.93e-05	2.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK1—melanoma	1.91e-05	2.67e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—melanoma	1.91e-05	2.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—melanoma	1.88e-05	2.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—melanoma	1.8e-05	2.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—melanoma	1.65e-05	2.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—melanoma	1.62e-05	2.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—melanoma	1.6e-05	2.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—melanoma	1.53e-05	2.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—melanoma	1.46e-05	2.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—melanoma	1.35e-05	1.9e-05	CbGpPWpGaD
